منابع مشابه
S3-selection of Patients for Tki Treatment
Patients with advanced DTC who are refractory to I treatment have a life expectancy of 36 years and represent a group for whom there is a clear unmet medical need (1). Radioiodine refractory thyroid cancer is not common, with an estimated incidence of four cases per million population year (5% of patients with clinical thyroid cancer, 250 patients per year in France) (2,3). It occurs more frequ...
متن کاملALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
PURPOSE EML4-ALK fusions define a subset of lung cancers that can be effectively treated with anaplastic lymphoma kinase (ALK) inhibitors. Unfortunately, the duration of response is heterogeneous and acquired resistance limits their ultimate efficacy. Thus, a better understanding of resistance mechanisms will help to enhance tumor control in EML4-ALK-positive tumors. EXPERIMENTAL DESIGN By ap...
متن کاملProgress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer.
To discuss the mechanism and clinical application of EGFR-TKI and ALK/ROS1 inhibitors in non-small cell lung cancer (NSCLC), we reviewed recent available data mainly from PubMed. We found that chemotherapy, progression-free survival (PFS), objective response rate (ORR), and quality of life of patients with advanced NSCLC can be greatly improved in these drugs medication compared with convention...
متن کاملFAM83A and FAM83B: candidate oncogenes and TKI resistance mediators.
The growth and survival of tumor cells can depend upon the expression of a single oncogene, and therapeutically targeting this oncogene addiction has already proven to be an effective approach in fighting cancer. However, it is also clear that cancer cells can adapt and become resistant to therapy through compensatory activation of downstream pathways that relieve the cell of its addicted pheno...
متن کاملEGFR/Met association regulates EGFR TKI resistance in breast cancer
Breast cancers show a lack of response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), despite 30% of tumors expressing EGFR. The mechanism of this resistance is unknown; however, we have recently shown that Met kinase activity compensates for loss of EGFR kinase activity in cell culture models. Met has been implicated in the pathogenesis of breast tumors and there...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2015
ISSN: 0923-7534
DOI: 10.1093/annonc/mdv434.04